Clinical trial · no report yet · Phase 1/Phase 2
LUPER
Lurbinectedin (PM01183) Combined With Pembrolizumab in Small Cell Lung Cancer.
- NCT04358237 ↗
- Completed
- Antonio Calles Blanco
- Standard
We haven't built a report for this trial yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Preliminary discovery
Commentary in our index that names this trial so far
Podcasts, YouTube videos and X posts we have indexed. A report screens them, searches for more and cites what clinicians said when it is built, so final coverage is set at build.
| Channel | Found | |
|---|---|---|
| X threads | 18 | |
| YouTube | 2 | |
| Podcasts | 1 |
The trial
ClinicalTrials.gov- Official title
- Phase I/II, Multicenter, Open-label, Clinical and Pharmacokinetic Study of Lurbinectedin (PM01183) in Combination With Pembrolizumab in Patients With Relapsed Small Cell Lung Cancer
- Phase
- Phase 1/Phase 2
- Status
- Completed
- Conditions
- Small Cell Lung Carcinoma
- Interventions
- Lurbinectedin; Pembrolizumab
- Arms
- Experimental: lurbinectedin (PM01183) + pembrolizumab · Experimental
- Enrollment
- 28
- Primary outcomes
- Phase I: Maximum tolerated dose (MTD) and recommended phase II dose (RD) of lurbinectedin in combination with pembrolizumab in patients with relapsed SCLC.
- Phase II: Efficacy of lurbinectedin in combination with pembrolizumab in terms of overall response rate (ORR), according to RECIST 1.1, in patients with relapsed SCLC.
- Sponsor
- Antonio Calles Blanco with MedSIR, PharmaMar, Merck Sharp & Dohme LLC
- Start
- Sep 21, 2020
- Primary completion
- Sep 30, 2023
- Results posted
- No
- Registry record
- NCT04358237 · updated Jun 4, 2025
Publications
linked from the registry- Calles A, Navarro A, Doger de Speville Uribe BG, Colome EA, de Miguel M, Alvarez R, Arregui M, Moreno V, Rocha P, Calvo E, Ramon-Patino J, Corral de la Fuente E, Alcala-Lopez D, Boix O, Fernandez-Pinto M, Rodriguez-Morato J, Palmero R, Nadal E, Jove M, Felip E. Lurbinectedin Plus Pembrolizumab in Relapsed SCLC: The Phase I/II LUPER Study. J Thorac Oncol. 2025 Jul;20(7):969-982. doi: 10.1016/j.jtho.2025.02.005. Epub 2025 Feb 10. PubMed 39938593